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Multiple myeloma(MM)isahumanB cellmalignancy characterized bythebone
marrow (BM) accumulation of plasma cells that secrete monoclonal Ig and cause
typical osteolytic lesions (1). By the time the disease is detected, it is already wide-
spread throughout the axial skeleton (1). Still, few plasma cells are seeninthe circu-
lation and only at the terminal phase ofthe disease, suggesting that MM may be
disseminated to the BM by circulating precursors (1, 2). Transplantation experi-
mentshave shown that the clonogenic cells are circulatingin murine plasmacytoma
(3). Four differentlines ofevidence favor a similar possibility in humans. First, pe-
ripheral B lymphocytes expressing the relevant idiotype have been described (4, 5).
Second, DNA-aneuploid cells have been detected in peripheral blood (PB) samples
(2). Third, plasma cell colonies may be grown from PB (6). Finally, PBMC may
show a monoclonal Ig gene rearrangement (7).
We reasoned that ifprecursors arecirculating theywill be revealed as monoclonal
plasma cells uponin vitroexposure to the proper growth anddifferentiation factors.
The present work shows that PBMC from patients with MM, cultured in presence
ofIL-3 andIL-6 for6 d, give origin to a population ofactively proliferatingB blasts
that differentiate into monoclonal plasma cells expressing, in each individual case,
the same L and H chain produced by BM malignant plasma cells. We conclude
that plasma cell precursors circulate in the peripheral blood of MM patients and
thattheir growth anddifferentiationareunderthe synergistic control ofIL-3 and IL-6.
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Materials and Methods
BriefDefinitive Report
Cells.
￿
PBMC wereobtainedby Ficoll-Hypaquegradientseparation from 11 patients with
MMat diagnosis, 5 menand 6women, and from 4normal subjects matched forageandsex.
Sevenpatientswereinstage I-II andfourwereinstage IIIaccordingtoDurie andSalmon (8).
Cytokines.
￿
rIL-1a(No. A-IL-1; Genzyme, Boston, MA), r-IL-1 #(No. B-IL-1), r-IL-3 (No.
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H-IL-3), r-IL-4 (No. H-IL-4) and r-IL-6 (No. H-IL-6, all from Genzyme) were used either
alone or in various combinations. The following concentrations were used: IL-1a + /3, 25-50
+ 25-50 U/ml; IL-3, 5-15 U/ml; IL-4, 500-1,000 U/ml; IL-6, 200-1,000 U/ml.
Antibodies.
￿
Polyclonal antibodies (Abs) to p, 6, y, a, K, and X chains directly conjugated
with tetraethylrhodamine (TRITC) were from Dakopatts, Glostrup, Denmark (No. R-152,
R-153, 8151, 8153, R-154, R-155). The following mAbs were used: anti-HLA-DR (No. 7360;
Becton Dickinson & Co., Mountain View, CA); CD3 (Leu 4, No. 7340); CD10 (anti-CALLA,
No. 7500; both Becton Dickinson & Co.); CD14 (MC1, No. 6602147 ; Coulter Immunology,
Hialeah, FL); CD19 (B4, No. 6603024; Coulter Immunology); CD38 (A10, reference 9), PCA-1
(No. 6603471, Coulter Immunology).
Cell Cultures.
￿
PBMC cells (2 x 106/ml) were cultured in 24 Limbro plates (Flow Labora-
tories, Irvine, CA) for up to 6 d at 37°C and 5% CO2 either alone or in presence of different
combinations of cytokines. Cell samples were harvested at days 3 and 6 and analyzed for
the morphology, DNA synthesis, and phenotype. The morphology was evaluated with con-
ventional May-Griinwald-Giemsa (MGG) staining on cytocentrifuge slides. The proportion
of cells in the S phase of the cell cycle was evaluated by adding bromodeoxyuridine (Brdu,
No. B-5002; Sigma Chemical Co., St. Louis, MO) at the final concentration of 10 'UM to
106 cells resuspended in RPMI medium. The cells were incubated for 1 h, washed, fixed (10),
and cytospins were obtained. Cells incorporating Brdu were identified in indirect immuno-
fluorescence (IF) by means of a specific anti-Brdu mAb (No. 7580, Becton Dickinson & Co.).
The phenotype was defined by double staining IF on cytospins air dried and fixed with cold
acetone (4°C). Polyclonal Abs were used in direct IF at 1 :50 final dilution. mAbs were used
in indirect IF either as culture supernatants in 1 :5 final dilution or as purified Ig at a final
dilution of2.5-lAg/ml and revealed by rabbit (R)-anti-mouse (M)-Ig labeled with FITC (No.
F-232, Dakopatts) and used at 1:10 dilution. A Zeiss epifluorescent microscopeequipped with
a planapochromat 63 x /1.4 oil immersion lens was used.
Results
MGG staining (Fig. 1 A) and IF studies with anti-Ig isotypes established that the
percentage ofplasma cells in the PBMC seeded at day 0 was between 0.01 and 0.2 %.
B cells (CD19+ cells) were 10.2 t 2.8%, T lymphocytes (CD3+ cells) were 63 t
10%, and monocytes (CD14` cells) were 15 ± 5%. The proportion of DNA-synthe-
sizing (Brdu +) cells was 0.13 t 0.06%. Preliminary experiments were performed
on these cultured MM PBMC to determine the optimal combinations and concen-
trations of cytokines using two parameters to assess the cytokine activity: (a) the
proportion of Brdu + cells after 3 d of culture and (b) the appearance of plasma cells
after 6 d ofculture. These experiments unequivocally showed that the combination
of IL-3 (15 U/ml) + IL-6 (1,000 U/ml)concomitantly added to the cultures at day 0
was strikingly active on MM PBMC cells (Table I). IL-1, IL-3, IL-4, and IL-6 used
alone as single stimuli and the varius combinations of IL-1 + IL-3, IL-1 + IL-4,
IL-1 + IL-6, IL-3 + IL-4, IL-4 + IL-6 concomitantly added at day 0 were instead
ineffective. Likewise inefficient was the priming of MM PBMC with IL-3 (or IL-6)
at day 0 followed by the addition of IL-6 (or IL-3) at day 3 . The simultaneous addi-
tion to the cultures at day 0 of IL-3 (15 U/ml) + IL-6 (1,000 U/ml) was therefore
used throughout the experiments. IL-3; IL-6-induced long-term cultures were not
attempted .
MMPBMC Culturedfor3dinthePresence ofIL-3 + IL-6 Give Origin to ProliferatingIm-
munoblast-like BCells. After 3 d of culture in presence ofIL-3 + IL-6, a population
of immunoblast-like cells (Fig. 1 B) appeared in all the MM samples studied (35
t 12.6%, range 20-62%, Table I). These large blasts were actively proliferating (8.5 f
2.5% Brdu+ cells, Table I) and belonged to the B cell lineage as they were HLA-' Control culture data in parentheses .
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FIGURE 1 .
￿
MM PBMC (A) were cultured in vitro in presence of IL-3 + IL-6 . After 3 d, large
immunoblast-like cells appeared (B, arrows) . After6 d, apopulation ofplasma cells was morpho-
logically evident (C) . These plasma cells were sometimes binucleated (D, arrow) and expressed
monoclonal Ig light and heavy chains (anti-kTRITC ; E) . PBMC from normal donors were
unaffected by the IL-3 + IL-6 combination (F) .
DR', uniformly expressed theB cell-specific CD19 andCD20 antigens (Table II),
while they didnot react with theTcell-specificCD3 andthe monocyte-specific CD14
mAbs (<I%) . Also, these cells were CD38+, but no Ig molecules could be observed
on their surface nor in the cytoplasm (Table II). In 3 of 11 cases, the vast majority
TABLE I
MM PBMC Cultured In Vitro in Presence of IL-3 + IL-6
Case Isotype Stage
Day 0
Plasma Brdu'
cells cells
%
Day
Blasts
%
3
Brdu' blasts
Day
Plasma cells
%
6
Brdu'
plasma cells
1 7X I 0.01 0.1 25 (2)' 8.1 (0.1)' 40 (2)' 1 .0
2 'yK I 0 .01 0.1 23 (1) 6.0 (0.2) 35 (2) 1 .0
3 UK II 0.05 0.1 20 (3) 7 .5 (0.1) 38 (1) 0.1
4 aK II 0.03 0.1 35 (4) 8 .3 (0.2) 42 (3) 0.1
5 yA II 0.03 0.1 30 (3) 9 .0 (0.3) 30 (2) 0.1
6 yX II 0.05 0.1 30 (5) 9.3 (0.1) 30 (2) 0.1
7 -YK II 0.1 0.1 30(2) 10(0.2) 35 (3) 0.1
8 X III 0.1 0.2 35 (4) 5.7 (0.3) 40 (3) 0.1
9 7K III 0.2 0.3 62 (7) 8.1 (0.5) 45 (5) 0.2
10 7K III 0.1 0.1 50 (4) 15 (1 .0) 35 (1) 0.5
11 yK III 0.1 0.2 45 (5) 6.6 (1 .0) 50 (4) 0.2
Mean 0.81 ± 0.13 ± 35 ± 12.6 8.5 ± 2.5 38.2 t 6.09 0.3 ± 0.3
± SD 0.05 0.06 (3 .6 t 1 .7) (0.4 t 0.3) (2.5 t 1 .2)
Normal
donors
(four
samples) <0.001 <0 .1 0.5±0 .3 <0 .5 0.6±0.3616 BERGUI ET AL.
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TABLE II
MM PBMC Cultured In Vitro in Presence of IL-3 + IL-6:
Phenotypic Features of Day 3 Blasts and Day 6 Plasma Cells
' Mean t SD of positive cases.
1 Weak reactivity.
5 Same light and heavy chain produced, in each case, by bone marrow plasma cells.
ofblasts (78, 85, 90%, respectively) expressed the CD10 antigen (Table II). These
three patients (Nos. 8, 9, 10; Table I) had an aggressive stage III MM and their
PBMC produced high numbers ofproliferating immunoblast-like cells. The per-
centage ofB blasts was 3.6 t 1.7% inMM control culture cellsand <I% in samples
from normal donors (Table I).
MMPBMC Culturedfor 6 d in Presence ofIL-3 + IL-6 Give Origin to MonoclonalPlasma
Cells. After 6 d ofcultureinthe presence of IL-3 + IL-6, apopulation ofmorpho-
logically evidentplasma cells (Fig. 1 C), sometimes binucleated (Fig. 1 D), became
apparent in all the MM samples studied (38.2 t 6.09%, range 30-50% ; Table I).
Some large blast-like cells were still present (15.5 t 4.7%) and these were incor-
porating Brdu, while the proportion ofBrdu + plasma cells was 0.3 t 0.3% (Table
I). The plasma cells were CD10 -, weakly CD19+, strongly CD38+, PCA-1' (Table
II). In 3 of 11 cases, the plasma cells expressed in the cytoplasm the same light and
heavy chain produced by the BM myeloma cells (Fig. 1 E): these were the three
cases who had produced CD10+ B blasts after 3d ofculture (Table I). Cytoplasmic
monoclonal light and heavy chains were expressed by the plasma cells ofall the re-
maining eight cases, when the initial signal provided by IL-3 + IL-6 was followed
by a refeeding of IL-6 (1,000 U/ml) at day 3. The proportion of morphologically
evident plasma cells was 2.5 t 1.2 % in MM control cultures and 0.6 t 0.3 (Table
I) in normal subjects (Fig. 1 F).
Discussion
In this paper we show that PBMC obtained from MM patientsharbor apopula-
tion of cells that, after exposure to IL-3 and IL-6, develop into proliferating
immunoblast-like B cells (Fig. 1 B) and subsequently differentiate into monoclonal
plasma cells (Fig. 1, C-E). Our findings demonstrate that malignant plasma cell
precursorscirculate inthePB ofMMpatients and establishthat theirterminal differen-
tiation ispromotedbythe concertedaction of IL-3 and IL-6. IL-3 supports the prolifer-
ation ofB cellprecursors inthe murine lymphohemopoietic system (11, 12) and has
been recently shown to be active also on human acute lymphoblastic leukemia B
blasts (13). IL-6 promotes thedifferentiation ofactivated B cells (14, 15), and in con-
Day 3
Positive/tested
blasts
Percent
Day 6 plasma
Positive/tested
cells
Percent
Surface Ig 0/11 <1 0/11 <I
Cytoplasmic Ig 0/11 <1 11/lls >95
HLA-DR 11/11 87 t 12 3/11 65 t 11'
CD 10 3/11 84 1 5' 0/11 3 t 2
CD 19 11/11 90 t 7 10/11 90 t 51
CD 38 11/11 92 t 7 11/11 91 f 6
PCA-1 4/11 75 t 9 11/11 85 t 6BERGUI ET AL.
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certwith IL-3, may also effect multipotential stem cells (16). Further, IL-6 receptors
are expressed onthe surface ofMM plasma cells(17) and indeed IL-6 not only con-
trols thegrowth ofmurine malignant plasma cells(18) but alsoinfluences theprolifer-
ation ofhuman MM cells (17, 19). It is unlikely that MM precursors have a plasma
cell morphology since, in our culture system, high numbers of monoclonal plasma
cellswereobtained at day 6 even when the plasma cells seeded at day 0were0.01%.
Likewise, CD10+ cells are not "the" clonogenic cells of MM but appear to repre-
sent ahyperactive transition compartment ofproliferatingpre-plasma cells (20). This
observation provides a biological explanation for the highly aggressive clinical be-
havior ofCD10+ MM, as aredefined the cases with ahigh proportion ofBM CD10+
B cells (21)that may eventually spillover in the PB (22). The IL-3/IL-6 responsive-
ness ofMM circulatingplasma cell precursors favors the view that the transforming
events of MM occur at an early stage of hematopoiesis (2, 5, 20).
Ourfindings suggestthe likely dynamicsofprecursor-plasma celltransition within
the MM malignantclone. MMplasma cell precursors have IL-3 andIL-6 receptors,
circulate and find the appropriate microenvironment enriched in IL-3 + IL-6 in
the BM, wheretheyfirst transforminto activelyproliferating blast-like cells possibly
expressing the CD10 antigen, and then they develop into monoclonal plasma cells.
This modelindicates that aclosecooperation between transformedcellsandcytokine-
producing cells may be a major mechanism in the progression ofMM (2) and also
has two apparent clinical implications. First, the culture ofPBMC in the presence
ofIL-3 + IL-6 may be a simple assay to monitor the patient's response to the treat-
ment and to assess a complete remission. Second, the burst ofproliferative activity
observed after 3 d ofculture ofPBMC in presence ofIL-3 + IL-6 may be applied
to the cytogeneticinvestigation of MM patients that is usually performed on BM
samples and provides unsatisfactory results because ofthe very low fraction ofcells
in DNA synthesis (23).
Summary
PBMC from 11 patients with multiple myeloma (MM) were cultured in vitro in
presence ofIL-3 and IL-6. After 3 d, actively proliferatingimmunoblast-like B cells
(20-62%) were apparent. After 6 d, apopulation ofmorphologically evident plasma
cells was observed (30-50%) that expressed, in each individual case, the same light
and heavy chain produced by bone marrow malignant plasma cells. We conclude
that in MM the malignant plasma cell precursors are circulating and their growth
and terminal differentiation are under the synergistic control of IL-3 and IL-6.
Receivedfor publication 8 May 1989 and in revisedform 31 May 1989.
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